{
  "$schema": "folio-library-entry/v1",
  "id": "10665-342365",
  "blocks": [
    {
      "id": "library/10665-342365/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 4,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "WHO guideline for screening and treatment \nof cervical pre-cancer lesions for cervical \ncancer prevention, second edition\nWHO guideline for screening and \ntreatment of cervical pre-cancer \nlesions for cervical cancer \nprevention, second edition\nWHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition\nISBN 978-92-4-003082-4 (electronic version)\nISBN 978-92-4-003083-1 (print version)\n© World Health Organization 2021\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO li",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover, ISBN and copyright page of the WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition (2021), with licence terms and disclaimers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Contents",
      "pageStart": 4,
      "pageEnd": 6,
      "target": "../sections/sec-000-contents.md",
      "narrative": null,
      "content": "v\nAcronyms and abbreviations\t\n\b\nvii\nExecutive summary\t \b\nviii\n\t\nBackground\t\n\b\nviii\n\t\nMethods\t\b\nviii\n\t\nSummary of screening and treatment recommendations to prevent cervical cancer\b x\n1. Introduction\t\n\b\n1\n\t\n1.1 Background\t \b\n1\n\t\n1.2 Approaches to screening and treatment\t\n\b\n3\n\t\n1.3 Rationale for this new edition of recommendations\t \b\n4\n\t\n1.4 Phased approach for the development of the recommendations\t\n\b\n5\n\t\n1.5 Target audience\t\n\b\n6\n2. Methods\t\n\b\n7\n\t\n2.1 Groups contributing to the guideline development process\t \b\n7\n\t\n2.2 Scoping review and appraisal of the existing recommendations\t\n\b\n9\n\t\n2.3 Prior",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The table of contents of the cervical pre-cancer screening and treatment guideline, followed by the start of the acknowledgements listing Guideline Development Group members and evidence contributors.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-001-acknowledgements.md",
      "narrative": null,
      "content": "Acknowledgements\nJames Killen, Gigi Lui, Diep Nguyen, Bernardo Nuche, Catherine Sauvaget, Holger Schünemann,  \nKate Simms, Ronaldo Silva, Karin Sundström, Katayoun Thaghavi, Cari van Schalkwyk and  \nBrian Williams.\nThe following individuals acted as observers at the GDG meeting: Benjamin Anderson, J. \n(Hans) Berkhof, Smiljka de Lussigny, Eduardo Franco, Lisa Pei-Ching Huang, Krishna Jafa, Jose \nJeronimo, Somesh Kumar, Ilana Lapidos-Salaiz, David Mesher, Jasantha Odayar, Groesbeck Parham, \nCarmen Pérez Casas, Felipe Roitberg and Heather Watts.\nThe WHO Secretariat included Maribel Almonte Pachec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the acknowledgements of the cervical cancer screening guideline, naming observers, WHO Secretariat members and others, and gives the list of acronyms and abbreviations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acronyms and abbreviations",
      "pageStart": 8,
      "pageEnd": 9,
      "target": "../sections/sec-002-acronyms-and-abbreviations.md",
      "narrative": null,
      "content": "Acronyms and abbreviations",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading for the acronyms and abbreviations section.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-003-background.md",
      "narrative": null,
      "content": "Cervical cancer is a leading cause of mortality among women. In 2020, an estimated 604 000 \nwomen were diagnosed with cervical cancer worldwide and about 342 000 women died from the \ndisease. Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading \ncause of cancer death in 36 countries. The vast majority of these countries are in sub-Saharan \nAfrica, Melanesia, South America, and South-Eastern Asia. \nIn May 2018, Dr Tedros Adhanom Ghebreyesus, World Health Organization (WHO) \nDirector-General, issued a call to action for the elimination of cervical cancer. In N",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the background to the cervical cancer guideline, citing about 604,000 new cases and 342,000 deaths in 2020, mostly in sub-Saharan Africa, Melanesia, South-Eastern Asia and South America. It recalls the Director-General's 2018 call for elimination and the 2020 global strategy targets, and notes that experts agreed to update and simplify screening and treatment recommendations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-004-methods.md",
      "narrative": null,
      "content": "This updated guideline for screening and treatment to prevent cervical cancer was developed in \nthree steps:",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A one-line lead-in stating that the updated guideline was developed in three steps.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 9,
      "pageEnd": 11,
      "target": "../sections/sec-005-executive-summary.md",
      "narrative": null,
      "content": "1.\n2.\n3.\nReview the current guidelines and identify recommendations to update or to develop \nde novo.  \nDevelop questions based on population (P), intervention (I), comparator (C) and \noutcomes (O) (PICO questions) for the recommendations and conduct new \nsystematic reviews or update those conducted for the previous guideline, and model \noutcomes when primary research was not available.  \nApply the Grading of Recommendations Assessment, Development and \nEvaluation (GRADE) methodology to assess the certainty of evidence and to \ndevelop recommendations using evidence-to-decision (EtD) tables.\nTh",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the three development steps for the cervical cancer guideline: reviewing existing recommendations, framing PICO questions with new or updated systematic reviews and modelling, and applying GRADE with evidence-to-decision tables. It describes the work of the Guideline Development Group from 2019 and defines the screen-and-treat and screen, triage and treat approaches.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of screening and treatment recommendations to prevent cervical cancer",
      "pageStart": 11,
      "pageEnd": 18,
      "target": "../sections/sec-006-summary-of-screening-and-treatment-recommendatio.md",
      "narrative": null,
      "content": "cervical cancer\nIn this present publication, there is a total of 23 recommendations and 7 good practice statements.\n•\t\nAmong the 23 recommendations, 6 are identical for both the general population of women and \nfor women living with HIV and 12 are different and specific for each population.\n•\t\nAmong the 7 good practice statements, 3 are identical for both the general population of \nwomen and for women living with HIV and 2 are different and specific for each population.\nIn Table 1 below we have grouped the recommendations and good practice statements in two \ncolumns for the general population",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the guideline's 23 recommendations and 7 good practice statements, explaining which apply identically to the general population of women and which differ for women living with HIV. A table pairs the recommendations for each group, starting with the strong recommendation to use HPV DNA detection rather than VIA or cytology as the primary screening test, followed by guidance on triage options, self-collected samples, starting age, screening intervals and follow-up. It gives the strength of each recommendation and certainty of evidence. It ends with summary strategies: HPV DNA screening from age 30 every 5 to 10 years for women generally, and from age 25 every 3 to 5 years with triage for women living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Recommendation and good practice statement for treatment not covered in previous guidelines",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table gives one good practice statement (no. 41, on the timing of treatment) and one recommendation (no. 42, on excision treatment for adenocarcinoma in situ) that apply to both the general population of women and women living with HIV, with the strength of recommendation and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-007-11-background.md",
      "narrative": null,
      "content": "Cervical cancer is a leading cause of mortality among women. In 2020, an estimated 604 000 \nwomen were diagnosed with cervical cancer worldwide and about 342 000 women died from the \ndisease. Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading \ncause of cancer death in 36 countries. The vast majority of these countries are in sub-Saharan \nAfrica, Melanesia, South America, and South-Eastern Asia (1).\nIn May 2018, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization \n(WHO), issued a call to action for the elimination of cervical ca",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Restates the global burden of cervical cancer and the 2030 elimination targets of 90% HPV vaccination, 70% screening and 90% treatment. It explains that cervical intraepithelial neoplasia is caused mainly by high-risk HPV types such as 16 and 18 and distinguishes low-grade lesions from high-grade pre-cancers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 18,
      "pageEnd": 20,
      "target": "../sections/sec-008-1-introduction.md",
      "narrative": null,
      "content": "2 Launch page: https://www.who.int/news-room/events/detail/2020/11/17/default-calendar/launch-of-the-global-strategy-to-accelerate-\nthe-elimination-of-cervical-cancer \nThe traditional method to screen women for cervical cancer has been cytology (the Papanicolaou \ntest, also known as the Pap smear or smear test). When cytology results are positive, the diagnosis \nis confirmed by colposcopy, and appropriate treatment is informed by biopsy of suspicious lesions \nfor histological diagnosis. In countries with effective cytology-based cervical cancer screening \nand treatment programmes, the mortalit",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews cervical screening methods, noting that cytology programmes have greatly cut mortality in some countries but have been less successful in low- and middle-income settings, and describes newer VIA and HPV DNA tests and tests under evaluation. A table groups molecular, cytologic and visual inspection tests, and the text explains the screen-and-treat approach, preferably in a single visit.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Approaches to screening and treatment",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-009-12-approaches-to-screening-and-treatment.md",
      "narrative": null,
      "content": "In this document, two approaches to screening and treatment are distinguished: the screen-and-treat \napproach and the screen, triage and treat approach.\nScreening and treatment approaches\n•\t In the “screen-and-treat approach”, the decision \nto treat is based on a positive primary screening \ntest only.  \n•\t In the “screen, triage and treat approach”, the \ndecision to treat is based on a positive primary \nscreening test followed by a positive second test \n(a “triage” test), with or without histologically \nconfirmed diagnosis.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the two approaches compared in the guideline: screen-and-treat, where treatment follows a positive primary test, and screen, triage and treat, which requires a second positive triage test.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for this new edition of recommendations",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-010-13-rationale-for-this-new-edition-of-recommendat.md",
      "narrative": null,
      "content": "Recommendations for screening and treatment to prevent cervical cancer, including for women \nliving with HIV, can be found in four existing WHO guidelines – on screening and treatment of \npre-cancer lesions, treatment for CIN2/3 and AIS, cryotherapy for CIN, and thermal ablation for \npre-cancer lesions (12–15). These recommendations (except for those on thermal ablation, published \nlater in 2019) were consolidated in the 2014 second edition of Comprehensive cervical cancer \ncontrol: a guide to essential practice (5), which also includes the WHO recommendations for HPV \nvaccination, treatment o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that earlier WHO cervical screening and treatment recommendations were spread across several guidelines and the 2014 comprehensive guide, and that this edition updates them in light of new evidence and the elimination strategy. It states the guideline's objective of improving national screening and treatment strategies for all women, including those living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Phased approach for the development of the recommendations",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-011-14-phased-approach-for-the-development-of-the-re.md",
      "narrative": null,
      "content": "The following are the four phases of the updates to WHO’s cervical cancer screening and treatment \nrecommendations. This guideline delivers the output of Phase 1.\nUpdate the recommendations on screening and treatment \nand the clinical algorithms for the most commonly used \nscreening and triage strategies for both women in general and \nthose living with HIV. \nEvaluate the evidence for the clinical algorithms that were not \nprioritized in Phase 1.\nDevelop recommendations for the implementation of these \nscreening and treatment strategies.\nEstablish a “living guideline” for screening and treatmen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines the four phases of updating WHO's cervical screening recommendations, from updating key algorithms (this guideline) to evaluating others, implementation guidance and a living guideline. It notes that the guideline also aims to clarify starting age, lifetime screens and screening intervals.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-012-15-target-audience.md",
      "narrative": null,
      "content": "This document is intended primarily for policy-makers, programme managers, programme officers \nand other professionals in the health sector who have responsibility for choosing strategies for \ncervical cancer prevention, at country, regional and district levels. Health-care professionals – such \nas doctors, nurses and community health workers working in reproductive health programmes, \nantenatal and postnatal services, family planning services, HIV/AIDS control programmes and in \nclinics that care for women at the district and primary health care levels – may also consult this \ndocument to und",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the guideline's audience as policy-makers, programme managers and health professionals involved in cervical cancer prevention, and notes that the term women is used for all people at risk of cervical cancer regardless of gender identity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-013-2-methods.md",
      "narrative": null,
      "content": "handbook for guideline development, second edition (18). A summary of the process is provided here.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A short lead-in stating that the guideline followed the WHO handbook for guideline development and summarising the process.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Groups contributing to the guideline development process",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-014-21-groups-contributing-to-the-guideline-developm.md",
      "narrative": null,
      "content": "Lists of all members of the Guideline Development Group (GDG), External Review Group (ERG), \nsystematic review teams, modelling teams and other contributors are provided in Annex 1, with details \nof their expertise and affiliations. The WHO Secretariat consisted of staff from various relevant WHO \ndepartments, and staff from the International Agency for Research on Cancer (IARC). The Steering \nGroup of the WHO Secretariat led the coordination of the development of this guideline. Members \nof the Secretariat who were not part of the Steering Group were kept informed of the guideline \ndevelopmen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the groups involved in developing the guideline, including the WHO and IARC Secretariat, Steering Group, Guideline Development Group, External Review Group and systematic review and modelling teams. It notes that much of the work was done virtually through online meetings, surveys and shared platforms.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Declarations and management of conflicts of interest",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-015-declarations-and-management-of-conflicts-of-inte.md",
      "narrative": null,
      "content": "After being invited to join the GDG by the WHO Secretariat at the beginning of the guideline \ndevelopment process, and in accordance with the WHO handbook for guideline development (18), \neach prospective GDG member completed a written declaration of interest (DOI) form. The DOIs \nwere reviewed by two members of the WHO Secretariat and no conflicts of interest were identified \n(Annex 3). The GDG members’ names and curriculum vitae were subsequently published on the \nWHO website for the Department of Sexual and Reproductive Health and Research and approved \nby the WHO Guidelines Review Committe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that Guideline Development Group members completed declarations of interest, which were reviewed and found to raise no conflicts, and were asked to report new interests at each meeting.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Confidentiality",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-016-confidentiality.md",
      "narrative": null,
      "content": "Each GDG member also signed a confidentiality agreement at the beginning of the GDG process, \nand the WHO Secretariat restated at the start of each GDG meeting that all discussions and draft \nrecommendations were to remain confidential until publication.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that group members signed confidentiality agreements and that discussions and draft recommendations were kept confidential until publication.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scoping review and appraisal of the existing recommendations",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-017-22-scoping-review-and-appraisal-of-the-existing.md",
      "narrative": null,
      "content": "In October 2019, a subgroup of the GDG met in Geneva to review the previously published \nrecommendations and decide which should be removed, validated, edited or updated based on \nnew evidence, and whether any new recommendations should be made for new interventions. \nThis process was informed by a scoping review of the literature and an assessment of changes in \ndisease burden, practice and policy. These decisions were circulated to all members of the GDG for \nfeedback, and agreement on which recommendations to keep, update and add was reached after \nadditional virtual meetings and electronic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the October 2019 scoping review of existing recommendations to decide which to remove, validate, update or add, and the approval of separate then merged scoping documents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority questions for review of evidence",
      "pageStart": 27,
      "pageEnd": 28,
      "target": "../sections/sec-018-23-priority-questions-for-review-of-evidence.md",
      "narrative": null,
      "content": "The GDG identified 14 overarching questions, framed using the population (P), intervention (I), \ncomparator (C), outcomes (O) (PICO) format, as a starting point for formulating recommendations \napplying to the general population of women and women living with HIV (Table 2.1).\nPICO 1 \nShould one screen-and-treat strategy versus another screen-and-treat strategy \nbe used in women? \nPICO 2 \nShould one screen, triage and treat strategy versus another screen, triage and \ntreat strategy be used in women?\nPICO \n3, 4, 5, 6, 7 \nShould women be followed up 12 and/or 24 months, or 3, 5 or 10 years after",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the 14 PICO questions guiding the evidence review, covering comparisons of screen-and-treat and triage strategies, follow-up intervals, starting age and strategies to support screening uptake, some deferred to a later phase.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Priority algorithms",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../sections/sec-019-24-priority-algorithms.md",
      "narrative": null,
      "content": "Since screening and treatment can be done using different primary screening and triage tests, \nthere are numerous possible combinations or algorithms. In December 2019, GDG members were \nsurveyed to prioritize the screening and/or triage tests and the treatments that should be evaluated. \nFollowing this prioritization exercise, a subgroup of GDG members met to review the results from \nthe survey and to agree on the algorithms to be prioritized. They reached a consensus to address \nseven priority algorithms in this first phase of the guideline update (Table 2.2; for detailed algorithms \nplease",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that a survey and subgroup meeting in December 2019 narrowed the many possible screening and triage combinations to seven priority algorithms for this phase.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Outcomes",
      "pageStart": 28,
      "pageEnd": 29,
      "target": "../sections/sec-020-25-outcomes.md",
      "narrative": null,
      "content": "The GDG agreed that the outcomes previously identified in the 2013 screening and treatment \nguideline (12) would also be the critical outcomes for the new PICO questions; the critical \noutcomes are listed in Table 2.3. To ensure coherence in the systematic reviews and modelling, \na working group (subgroup of the GDG) developed standardized definitions for these outcomes \n(see Annex 5). After reviewing the evidence and modelling a limited number of outcomes, the GDG \nagreed to consider all outcomes together. Adverse events were defined as outcomes that were a \ndirect consequence of pre-cancer t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the critical outcomes carried over from the 2013 guideline, including cancer incidence and mortality, detection of pre-cancer, preterm birth and grouped adverse events of treatment, along with costs, feasibility and equity.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2.2. The seven algorithms considered",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../tables/table-2-2.csv",
      "narrative": "draft",
      "content": "The table lists the seven priority screening and treatment algorithms evaluated for the guideline, grouped into screen-and-treat approaches (1–2) and screen, triage and treat approaches (3–7).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Syntheses of evidence",
      "pageStart": 29,
      "pageEnd": 32,
      "target": "../sections/sec-021-26-syntheses-of-evidence.md",
      "narrative": null,
      "content": "Evidence was synthesized for each PICO question according to the methods in the WHO handbook \nfor guideline development and the Cochrane handbook for systematic reviews of interventions (18,20). \nThe literature review performed for the development of the IARC handbooks of cancer prevention: \ncervical cancer screening, Vol. 18 (to be published in 2021; referred to in brief throughout this \nguideline as “IARC handbook”) (21) was also part of the evidence synthesized for the development \nof this guideline. We used a hierarchical approach to avoid the duplication of reviews that had been \nprevious",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how evidence was synthesised using WHO and Cochrane methods, drawing on the forthcoming IARC handbook and updating existing reviews where possible. A table maps each type of evidence, such as systematic reviews, modelling and surveys, to the related recommendations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods used for systematic literature reviews",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../sections/sec-022-261-methods-used-for-systematic-literature-revie.md",
      "narrative": null,
      "content": "The detailed methods for each review are reported in the Annex A, Supplementary Materials \n(Table 2.4). In brief, the systematic review teams applied the following key methods across all \nsystematic reviews for this guideline:\n•\t\ndevelop a systematic review protocol with inclusion and exclusion criteria for studies based on \nthe finalized PICO questions;  \n•\t\nsearch multiple databases (including MEDLINE, Embase and the Cochrane Library \nEpistemonikos) and clinical trial registries, contact investigators in the field for potentially \nrelevant systematic reviews, and look at randomized and non-r",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the methods used in the systematic reviews, from protocols and database searches to risk-of-bias assessment, synthesis and GRADE certainty ratings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Individual patient data meta-analysis",
      "pageStart": 33,
      "pageEnd": 34,
      "target": "../sections/sec-023-262-individual-patient-data-meta-analysis.md",
      "narrative": null,
      "content": "We conducted an individual patient data meta-analysis (IPD-MA) to analyse age-specific data for \ncervical cancer and CIN in women living with HIV. We contacted the authors of the studies identified \nin the systematic review of screening-initiation age (Web annex A, Supplementary material 5) that \nincluded at least 40 women living with HIV with CIN2+. All the data sets they provided were first \nreviewed individually, then discrepancies were resolved with investigators, and the aligned data sets \nwere then combined. The IPD-MA used one-stage (22) random study intercept models to take into \naccou",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes an individual patient data meta-analysis of age-specific cervical lesion data in women living with HIV, using random-effects models to estimate screening results by age and HIV status.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mathematical modelling",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/sec-024-263-mathematical-modelling.md",
      "narrative": null,
      "content": "We used the Policy1-Cervix platform, an extensively validated dynamic model of HPV transmission, \nvaccination, type-specific natural history, cancer survival, screening, diagnosis and treatment \n(23–31), to predict outcomes in women across all 78 low- and middle-income countries. The \nPolicy-Cervix HIV-HPV model for cervical cancer among women living with HIV was used to \nevaluate outcomes for women living with HIV in the United Republic of Tanzania (32), as there was \nsufficient local data available on cervical cancer control activities and HIV disease burden and \ncontrol activities (includin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the Policy1-Cervix model was used to project outcomes for 78 low- and middle-income countries, with an HIV-HPV model applied to the United Republic of Tanzania. Outcomes modelled included cancer incidence and mortality, treatments, preterm births and cost-effectiveness.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Values and preferences",
      "pageStart": 34,
      "pageEnd": 35,
      "target": "../sections/sec-025-264-values-and-preferences.md",
      "narrative": null,
      "content": "A search for studies and systematic reviews was conducted that addressed, among other \nconsiderations, the values and preferences of end-users, health-care providers and other \nstakeholders. The literature was organized by study design and methodology, location and \npopulation, and presented to the GDG.\nFor primary data, all women and girls aged 15 years and older, regardless of their prior cervical \ncancer screening or treatment status, were eligible to participate in an anonymous, voluntary \nsurvey distributed via SurveyMonkey. The survey received approval from the WHO Ethics Review \nCommitt",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes a literature search on values and preferences and an anonymous online survey of 561 women and girls run in English and French in 2020.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Feasibility, acceptability, resources and equity considerations",
      "pageStart": 35,
      "pageEnd": 35,
      "target": "../sections/sec-026-265-feasibility-acceptability-resources-and-equi.md",
      "narrative": null,
      "content": "A survey of the GDG members was administered via SurveyMonkey to assess the implementation \nconsiderations for each priority algorithm. The survey was developed using the context and \nimplementation of complex interventions (CICI) framework (33). Each GDG member was asked \nabout their level of concern about each algorithm being able to sustainably meet the large-scale \ngoal of cervical cancer elimination. The following components of cervical cancer screening and \nmanagement service delivery were queried separately according to the priority algorithm: demand \ngeneration, access to screening and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes a survey of Guideline Development Group members, using the CICI framework, on concerns about implementing each priority algorithm at scale across service components and stakeholder levels.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Development of the recommendations",
      "pageStart": 35,
      "pageEnd": 36,
      "target": "../sections/sec-027-27-development-of-the-recommendations.md",
      "narrative": null,
      "content": "All the GDG meetings that focused on formulation of recommendations were held virtually. Tables \nto facilitate decision-making for recommendations – evidence-to-decision (EtD) tables – were \nproduced by the guideline methodologist for each recommendation and circulated to the GDG \nmembers before each meeting. These tables included a summary of the evidence (benefits and \nharms), relevant values and preferences information, and other issues, including use of resources \nand cost, feasibility, equity and acceptability.\nDuring the meeting, the EtD tables and evidence were discussed with the GDG. F",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how evidence-to-decision tables were prepared and discussed virtually, how members gave input and voted through GRADEpro, and how recommendations were finalised. A table explains what strong and conditional recommendations mean for different audiences.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Management of the external peer review",
      "pageStart": 36,
      "pageEnd": 37,
      "target": "../sections/sec-028-28-management-of-the-external-peer-review.md",
      "narrative": null,
      "content": "The draft guideline document was circulated to the External Review Group (ERG) for comment. The \nWHO Secretariat prepared a summary table with all ERG responses and sorted the comments by \ntopic or section. The WHO Secretariat then identified comments for discussion and presented these \nto the GDG, and when these issues had been resolved via email correspondence, the guideline \ndocument was finalized.\nTable 2.6 describes how strong and conditional recommendations should be interpreted. \nAdditionally, the GDG provided good practice statements when it agreed that this guidance was \nneeded, but a",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how external peer review comments were handled and how good practice statements were used. It also notes that even one or two lifetime screens can reduce mortality where no routine programme exists and that implementation guidance will follow.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Programme considerations",
      "pageStart": 37,
      "pageEnd": 37,
      "target": "../sections/sec-029-31-programme-considerations.md",
      "narrative": null,
      "content": "It is appropriate that a multidisciplinary health ministry team, which can consider different factors \nand make informed decisions, chooses which algorithm (or algorithms) to include in a national \nprogramme. The choice will vary by country – and in different settings within country programmes – \nand will depend on available resources, feasibility and acceptability. \nDecisions are also needed about when and who to contact for follow-up care. This guideline \nmakes recommendations that distinguish between three clinical scenarios in routine screening \nprogrammes:\nRegular screening intervals: Thi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises that a multidisciplinary ministry team choose national screening algorithms according to resources, feasibility and acceptability, and distinguishes clinical scenarios for follow-up such as regular screening intervals. It encourages population-based programmes that ensure treatment of women who screen positive.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Important considerations for the recommendations",
      "pageStart": 37,
      "pageEnd": 38,
      "target": "../sections/sec-030-3-important-considerations-for-the-recommendatio.md",
      "narrative": null,
      "content": "recommendations\nand call-and-recall efforts are important aspects of appropriate management to ensure that women \nare coming back to the service for treatment and follow-up. For the continuity and completeness of \ncare, strong links need to be established between the multiple levels of the health service (primary \nand secondary care) and individual patients. A further description of quality assurance and more \ndetailed programmatic guidance can be found in Annex 6 and in other published documents \n(5,35,36).\nCervical cancer screening and treatment should be provided to transgender men, and non",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses screening registries, call-and-recall and links between care levels, and states that screening and treatment should be offered to transgender men, non-binary and intersex people with a cervix, with services made more inclusive.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screening and triage tests considered in these guidelines",
      "pageStart": 38,
      "pageEnd": 40,
      "target": "../sections/sec-031-32-screening-and-triage-tests-considered-in-thes.md",
      "narrative": null,
      "content": "High-risk HPV DNA tests: These tests identify a group of high-risk carcinogenic \nHPV genotypes, typically including up to 14 types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, \n56, 58 and 59, which are Group 1 carcinogens, and HPV66 and 68) (37). HPV16 and \n18 are the highest-risk genotypes and are the most common in cancers. Some of the \ntests on the market provide information about specific HPV genotypes, such as HPV16 \nand 18. We refer to HPV tests with partial genotyping when they report HPV16 and 18 \n(including HPV45 in some cases) and other carcinogenic types separately. Other HPV \ntests may",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the screening and triage tests considered, including high-risk HPV DNA tests with partial or extended genotyping, cytology, VIA and colposcopy. It explains how they are combined in algorithms, such as HPV testing followed by VIA triage to decide treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment considerations",
      "pageStart": 40,
      "pageEnd": 41,
      "target": "../sections/sec-032-33-treatment-considerations.md",
      "narrative": null,
      "content": "In a screen-and-treat approach, women who screen positive are treated without histological \ndiagnosis. The treatment aims to destroy or remove the transformation zone of the cervix, or remove \nareas of the cervix that have been identified as abnormal by screening.\nThe methods of treatment may be ablative (destroying abnormal tissue by heating it with thermal \ncoagulation or freezing it with cryotherapy) or excisional (surgically removing abnormal tissue with \nLLETZ or CKC) (Annex 5, section 5.4). Ablative treatments do not result in a tissue specimen for \nhistological evaluation.\nIn this guide",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains treatment options for cervical pre-cancer, distinguishing ablative methods (thermal ablation, cryotherapy) from excisional ones (LLETZ, cold knife conization), and restates the count of recommendations and good practice statements.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Recommendations and good practice statements on screening and treatment",
      "pageStart": 41,
      "pageEnd": 44,
      "target": "../sections/sec-033-4-recommendations-and-good-practice-statements-o.md",
      "narrative": null,
      "content": "of women (section 4.1, nos. 1–14) and then for women living with HIV (section 4.2, nos. 21–34), and \nfinally an additional recommendation and good practice statement regarding treatment for all \nwomen are presented (section 4.3, nos. 41 and 42).5\n4.1 Recommendations and good practice statements: general \npopulation of women6 \n \nAll screening algorithms are in Annex 4.\n1.\t\nWHO recommends using HPV DNA detection as the primary screening test rather than \nVIA or cytology in screening and treatment approaches among both the general population of \nwomen and women living with HIV.* \n[Strong recommen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the recommendations and good practice statements for the general population of women, starting with HPV DNA detection as the preferred primary screening test and covering triage, sample collection, age to start and stop screening, intervals and follow-up. It ends with the summary strategy of HPV DNA screening from age 30 every 5 to 10 years, with or without triage.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Justification",
      "pageStart": 44,
      "pageEnd": 45,
      "target": "../sections/sec-034-411-justification.md",
      "narrative": null,
      "content": "A strong recommendation was made for using HPV DNA detection as a primary screening test \nwhen part of a screen-and-treat approach or a screen, triage and treat approach because a higher \nvalue was placed on the greater reductions in cervical cancer and deaths that are likely with HPV \nDNA detection compared with using VIA or cytology as a primary screening test (moderate-\ncertainty evidence). There may also be fewer harms, such as preterm deliveries, when screening \nwith an HPV DNA test compared with VIA. HPV DNA testing by the provider or by self-sampling \nmay have similar effects, so either",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the justification for the recommendations, chiefly the greater reductions in cancer and deaths with HPV DNA testing than with VIA or cytology, possible fewer harms and the acceptability of provider or self-sampling. It also justifies the chosen starting age, intervals and follow-up timings, based mostly on low-certainty evidence and modelling.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of the evidence",
      "pageStart": 45,
      "pageEnd": 48,
      "target": "../sections/sec-035-412-summary-of-the-evidence.md",
      "narrative": null,
      "content": "For further details on the following, refer to the summaries in Web annex A (Syntheses of the evidence) \nand Web annex B (EtD tables) – web links provided at the end of the Table of Contents.\nPrimary screening tests (Recommendations 1, 3 and 4): The GDG considered evidence for the \neffects of different primary screening tests and found moderate-certainty evidence from a synthesis \nof two randomized controlled trials and modelling that HPV DNA testing followed by treatment \nis more likely to lead to greater reductions in CIN2+ lesions, advanced (stage II+) cervical cancer \nand cervical cancer d",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the evidence behind the cervical screening recommendations for the general population of women, finding moderate-certainty evidence from trials and modelling that HPV DNA testing reduces pre-cancer, advanced cancer and deaths more than VIA, with lower risk after a negative HPV test than after negative cytology. It reports similar benefits for screen-and-treat and triage approaches, slightly fewer cancers with HPV16/18 genotyping triage, and likely similar performance of self-collected samples. It reviews evidence on starting screening at 30 versus 35, stopping age, screening intervals and follow-up timing, weighing benefits against treatments, preterm births and costs. It notes practical concerns about longer follow-up intervals and the transition from VIA or cytology to HPV testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Recommendations and good practice statements: women living with HIV",
      "pageStart": 48,
      "pageEnd": 51,
      "target": "../sections/sec-036-42-recommendations-and-good-practice-statements.md",
      "narrative": null,
      "content": "with HIV7 \n21.\t WHO recommends using HPV DNA detection as the primary screening test rather than \nVIA or cytology in screening and treatment approaches among both the general population of \nwomen and women living with HIV.* \n[Strong recommendation, moderate-certainty evidence] \n \nRemarks: Existing programmes with quality-assured cytology as the primary screening test should \nbe continued until HPV DNA testing is operational; existing programmes using VIA as the primary \nscreening test should transition rapidly because of inherent challenges with quality assurance.\n22.\tWHO suggests using an HPV",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out the recommendations and good practice statements for women living with HIV, including HPV DNA primary screening, use of triage after a positive HPV test, triage options and provider or self-collected samples. It covers starting age, intervals and follow-up after treatment or negative triage, and ends with the summary strategy of HPV DNA screening with triage from age 25 every 3 to 5 years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Justification",
      "pageStart": 51,
      "pageEnd": 52,
      "target": "../sections/sec-037-421-justification.md",
      "narrative": null,
      "content": "For women living with HIV, a strong recommendation was made for using HPV DNA testing as a \nprimary screening test because a higher value was placed on the reductions in cervical cancer and \ndeaths that are likely with this approach than on the potential harm that may occur, such as preterm \ndeliveries (moderate-certainty evidence). When compared with VIA or cytology as a primary \nscreening test, greater benefits are also more likely with HPV DNA testing. HPV DNA testing \nis acceptable to women and providers, is feasible and is not likely to lead to inequities. In some \nsettings, HPV DNA testi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Justifies the recommendations for women living with HIV, citing the greater cancer and death reductions from HPV DNA testing, its acceptability and feasibility, and the reduced harms from adding triage. It also explains the chosen screening intervals and follow-up timings, mostly on low-certainty modelled evidence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of the evidence",
      "pageStart": 52,
      "pageEnd": 55,
      "target": "../sections/sec-038-422-summary-of-the-evidence.md",
      "narrative": null,
      "content": "For further details on the following, refer to the summaries in Web annex A (Syntheses of the \nevidence) and Web annex B (EtD tables) – web links provided at the end of the Table of Contents.\nPrimary screening tests (Recommendations 21, 23 and 24): Moderate-certainty evidence \nfrom a randomized controlled trial, longitudinal studies and modelling found that HPV DNA as the \nprimary screening test in screening and treatment services is likely to result in greater reductions \nin CIN2+ than VIA, but may result in similar reductions to cytology (followed by colposcopy). There \nmay be similar harms",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the evidence for the recommendations for women living with HIV, finding that HPV DNA primary screening likely reduces pre-cancer more than VIA and similarly to cytology, and that triage may reduce harms through fewer treatments. It reports modelled benefits of three- to five-year intervals, the likely validity of self-sampling, and a good practice statement to screen at least twice in a lifetime. It also reviews individual patient data and modelling on starting age, follow-up intervals and uncertainties in applying general population results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Additional recommendation and good practice statement for treatment not covered",
      "pageStart": 55,
      "pageEnd": 55,
      "target": "../sections/sec-039-43-additional-recommendation-and-good-practice-s.md",
      "narrative": null,
      "content": "for treatment not covered in previous guidelines for the general \t\n\t population of women and women living with HIV\n41.\t Once a decision to treat a woman is made – whether from the general population of women or \nwomen living with HIV – it is good practice to treat as soon as possible within six months \nto reduce the risk of loss to follow-up. However, in women who are pregnant, good practice \nincludes deferral until after pregnancy. \n \nIn circumstances when treatment is not provided within this time frame, it is good practice to \nre-evaluate the woman before treatment. \n[Good practice statemen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives a good practice statement to treat women within six months of a decision to treat (deferring until after pregnancy and re-evaluating if delayed) and a conditional recommendation for LLETZ or cold knife conization for adenocarcinoma in situ.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Justification and evidence summary",
      "pageStart": 55,
      "pageEnd": 56,
      "target": "../sections/sec-040-431-justification-and-evidence-summary.md",
      "narrative": null,
      "content": "Low-certainty evidence from a systematic review of the literature found that there may be little to \nno difference in the recurrence rate of AIS with CKC or electrosurgical excision, or in the incidence \nof complications such as major infection and bleeding, and found that more women may have \npremature deliveries in subsequent pregnancies following a CKC compared with electrosurgical \nexcision. The studies included in the systematic review did not confirm HIV status, but the GDG \nagreed that the data could be extrapolated to women living with HIV and applied directly. CKC is \nperformed in the",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises low-certainty evidence showing little difference in recurrence or complications between cold knife conization and loop excision for adenocarcinoma in situ, but more preterm births after conization, which is also costlier and less accessible. It then lists research gaps on HPV genotyping, screening strategies and starting age for women living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research gaps and further considerations",
      "pageStart": 56,
      "pageEnd": 58,
      "target": "../sections/sec-041-5-research-gaps-and-further-considerations.md",
      "narrative": null,
      "content": "8 All the PICO questions are listed in Table 2.1, in Chapter 2. \nTiming of treatment after positive screening or diagnosis (PICO 9 and 10)\nThe GDG noted that in women living with HIV, more research is needed about the efficacy of CKC \nand LLETZ in the treatment of AIS. Evidence is needed for the costs and cost-effectiveness of CKC \nversus LLETZ for AIS in both the general population of women and in women living with HIV. \nFor the future implementation recommendations (Phase 3; see section 1.4), the GDG also discussed \nsome research gaps to be addressed. One would be the integration of screenin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes further research gaps, including treatment of adenocarcinoma in situ in women living with HIV, cost-effectiveness of excision methods, integrating screening into HIV programmes, loss to follow-up after positive screening, and training costs when moving to HPV testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline dissemination and impact",
      "pageStart": 58,
      "pageEnd": 58,
      "target": "../sections/sec-042-61-guideline-dissemination-and-impact.md",
      "narrative": null,
      "content": "The final published guideline document will be disseminated using WHO's worldwide network \nto make sure that the guideline reaches health-care providers and programme managers so that \nthe most recent evidence is integrated and accessible for clinical decision-making to prevent \ncervical cancer. A link to download the guideline will be available at the WHO website and in HRP \nNews,9 and printed copies, if requested, will be disseminated to health ministries, WHO country \nand regional offices, WHO collaborating centres on cervical cancer, and other cervical cancer \ncollaborators and partners.\nT",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes plans to disseminate the cervical screening guideline through WHO networks, its website, printed copies, high-level meetings, conferences and policy briefs, with regional workshops to support national adaptation and partnership with UN agencies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Dissemination and updating of the guidelines",
      "pageStart": 58,
      "pageEnd": 59,
      "target": "../sections/sec-043-6-dissemination-and-updating-of-the-guidelines.md",
      "narrative": null,
      "content": "9 Subscribe using the link at the end of this web page: https://www.who.int/reproductivehealth/news/en/ \nEnergy Agency (IAEA) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) (39).  \nThe guideline will be disseminated at upcoming major conferences related to sexual and \nreproductive health and rights, HPV, HIV and public health. Other WHO guidance is available to \nsupport impact evaluation, national programme reviews, planning, implementation and scale-up \n(40,41,42). \nIn addition, impact will be measured by developing and disseminating surveys for both health \nworkers and clients,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the dissemination plans, mentioning conferences and supporting WHO guidance, surveys of health workers and clients a year after release to measure impact, and a planned revision of WHO's comprehensive cervical cancer control guide.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline update",
      "pageStart": 59,
      "pageEnd": 60,
      "target": "../sections/sec-044-62-guideline-update.md",
      "narrative": null,
      "content": "In this guideline, the GDG prioritized seven algorithms. Additional algorithms that will be covered \nin a future version of this guideline will include the use of HPV mRNA detection, DNA methylation, \np16/Ki-67 dual-staining cytology and automated visual evaluation. Evidence for the sensitivity and \nspecificity of these tests and the impact on important outcomes of using them in programmes \nis accumulating, and syntheses of this evidence are needed. These syntheses will be used in a \ncontinual process to develop new recommendations, as “living recommendations” in Phase 4 of the \nguideline upda",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that future versions will evaluate further tests such as HPV mRNA, DNA methylation, p16/Ki-67 dual staining and automated visual evaluation, and that Phase 4 will establish living recommendations updated as new evidence emerges.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 60,
      "pageEnd": 64,
      "target": "../sections/sec-045-references.md",
      "narrative": null,
      "content": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer \nstatistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in \n185 countries. CA Cancer J Clin. 2021:71:209–49. doi:10.3322/caac.21660. \n2.\t Global strategy to accelerate the elimination of cervical cancer as a public health \nproblem. Geneva: World Heatlh Organization; 2020 (https://www.who.int/publications/i/\nitem/9789240014107). \n3.\t Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, \nVol. 90. Lyon: International Agency for Research o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the cervical pre-cancer screening and treatment guideline, citing mainly cancer statistics, WHO strategies and guidance, IARC monographs and screening studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexes",
      "pageStart": 64,
      "pageEnd": 65,
      "target": "../sections/sec-046-annexes.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1: Guideline groups",
      "pageStart": 65,
      "pageEnd": 75,
      "target": "../sections/sec-047-annex-1-guideline-groups.md",
      "narrative": null,
      "content": "Guideline Development Group (GDG) members\nGDG Co-Chairs: Julie Torode and Mike Chirenje\nWHO region\nLast name\nFirst name\nInstitution\nCountry\nAfrican\nAchieng\nClaire Judith \nIkate\nUganda Cancer Society \nUganda\nAfrican\nAwori \nRuth\nRepresentative from \ncommunities of women \nliving with HIV\nUganda\nAfrican\nChinula\nLameck\nKamuzu Central Hospital\nMalawi\nAfrican\nChirenje\nMike\nUniversity of Zimbabwe \nZimbabwe\nAfrican\nChung\nMichael\nAga Khan University\nKenya\nAfrican\nDenny\nLynette\nUniversity of Cape Town\nSouth Africa\nAfrican\nDiop\nMamadou\nJoliot Curie Cancer Institute \nSenegal\nAfrican\nHappy\nMargaret \nAdvocac",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1, listing members of the Guideline Development Group by WHO region and institution, along with other contributors and the WHO and IARC Secretariat.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 2. Evidence-gathering teams and guideline task groups",
      "pageStart": 75,
      "pageEnd": 77,
      "target": "../sections/sec-048-annex-2-evidence-gathering-teams-and-guideline-t.md",
      "narrative": null,
      "content": "PICO 1 and 2\nPICO 1 and 2\nPICO 3, 4, 5, 6, \n7, 8\nPICO 3, 4, 7, 8\nPICO 9, 10\nScreen-\nand-treat \nScreen, triage \nand treat \n(follow-up \nstudies)\nScreen-\nand-treat\nScreen, triage \nand treat \n(diagnostic \nstudies)\nFollow-up after \npositive or \nnegative tests\nFollow-up after \npositive or \nnegative tests \nin women living \nwith HIV\nDuration \nbetween test \nand treatment\nTreatment \nof cervical \nintraepithelial \nneoplasia \n(severity)\nLead: Beatrice \nLauby-Secretan\nLead: Marc \nArbyn and Helen \nKelly\nLead: Nancy \nSantesso \nLead: Karin \nSundström\nLead: Catherine \nSauvaget \nVéronique \nBouvard\nIciar Indave\nI",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 2, a table of the evidence-gathering teams and task groups for each set of PICO questions, naming leads and members for reviews, modelling and the IARC handbook.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 3. Declarations of interests",
      "pageStart": 77,
      "pageEnd": 80,
      "target": "../sections/sec-049-annex-3-declarations-of-interests.md",
      "narrative": null,
      "content": "Last name\nFirst name\nDeclaration of \ninterests\nConfidentiality \nagreement\nAfrican\nAchieng\nClaire Judith \nIkate\nNo interests \ndeclared\nReceived\nAfrican\nAwori \nRuth\nNo interests \ndeclared\nReceived\nAfrican\nChinula\nLameck\nNo interests \ndeclared\nReceived\nAfrican\nChirenje\nMike\nNo interests \ndeclared\nReceived\nAfrican\nChung\nMichael\nNo interests \ndeclared\nReceived\nAfrican\nDenny\nLynette\nNo interests \ndeclared\nReceived\nAfrican\nDiop\nMamadou\nNo interests \ndeclared\nReceived\nAfrican\nHappy\nMargaret \nNo interests \ndeclared\nReceived\nAfrican\nIngbian\nPriscilla \nNo interests \ndeclared\nReceived\nAfrican\nKapambwe\nSha",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 3, a table showing that each Guideline Development Group member declared no interests and returned a confidentiality agreement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 4. Seven algorithms prioritized for Phase 1 of the guideline update",
      "pageStart": 80,
      "pageEnd": 90,
      "target": "../sections/sec-050-annex-4-seven-algorithms-prioritized-for-phase-1.md",
      "narrative": null,
      "content": "PRIORITIZED FOR PHASE 1 OF THE \nGUIDELINE UPDATE\nScreen-and-treat approaches:\n1.\t Visual inspection with acetic acid (VIA) as the primary screening test, followed by treatment \n2.\t HPV DNA (self- or clinician-collected) as the primary screening test, followed by treatment \n \nScreen, triage and treat approaches: \n3.\t Cytology as the primary screening test, followed by colposcopy triage, followed by treatment \n4.\t HPV DNA as the primary screening test, followed by HPV16/18 triage (when already part of \nthe HPV test), followed by treatment, and using VIA triage for those who screen negative for",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 4, listing the seven screening algorithms prioritised for the first phase, two screen-and-treat and five screen, triage and treat, combining VIA, HPV DNA, cytology, genotyping and colposcopy. It presents flow diagrams for each algorithm for the general population and women living with HIV, including follow-up and re-treatment steps.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 5. Standardized definitions used in this guideline",
      "pageStart": 90,
      "pageEnd": 112,
      "target": "../sections/sec-051-annex-5-standardized-definitions-used-in-this-gu.md",
      "narrative": null,
      "content": "DEFINITIONS USED IN THIS \nGUIDELINE\n5.1. Eligibility for ablative treatment\nWomen who screen positive with a human papillomavirus (HPV) nucleic acid amplification test \n(NAAT) are assessed for eligibility for ablative treatment so that women with or without a visible \nlesion (or lesions), who are eligible for ablation, can receive an ablative treatment (see section 5.1.2).\nAn assessment of eligibility for ablative treatment is done by identifying the transformation zone \ntype (i.e. the visibility and position of the transformation zone) (see section 5.1.1), and the location \nand size of the le",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 5, giving the standardised definitions used in the guideline, starting with eligibility for ablative treatment based on transformation zone type and lesion size and criteria for referral. It defines outcomes such as persistent, residual or recurrent disease and other clinical endpoints used in the reviews. It also defines the treatment methods, including thermal ablation, cryotherapy, LLETZ, cold knife conization and small-loop biopsy. Diagrams illustrate the three types of transformation zone.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-342365/blocks/figure-img-p110-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 110,
      "pageEnd": 110,
      "target": "../images/img-p110-1.webp",
      "narrative": "draft",
      "content": "Three schematic drawings of the cervix viewed from the front, stacked vertically: a pink circle with a central red area of varying size and position around the os, each with leader lines whose labels are not part of the image. In the surrounding annex text, such drawings accompany the description of transformation zone types 1, 2 and 3.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-342365/blocks/figure-img-p110-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 110,
      "pageEnd": 110,
      "target": "../images/img-p110-2.webp",
      "narrative": "draft",
      "content": "Three schematic cross-section drawings of the cervix and cervical canal, stacked vertically, with red segments marking the epithelium at and inside the canal opening to differing extents and leader lines whose labels are not part of the image. They appear alongside the front-view drawings of transformation zone types 1, 2 and 3.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-342365/blocks/prose-sec-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 6. Additional information for screening and treatment recommendations",
      "pageStart": 112,
      "pageEnd": 115,
      "target": "../sections/sec-052-annex-6-additional-information-for-screening-and.md",
      "narrative": null,
      "content": "INFORMATION FOR SCREENING AND \nTREATMENT RECOMMENDATIONS\nQuality assurance: A quality-assured programme is one that is monitored to give assurance that \nthe results consistently achieve the highest level of accuracy and reliability for the detection and \ntreatment of cervical abnormalities by the modality chosen.\nOther programme information: Screening registries, and call-and-recall efforts to ensure that \nwomen are managed appropriately are essential for both organized and opportunistic programmes. \nStrong links need to be established between individual patients and the multiple levels of hea",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 6, giving additional information on quality assurance, screening registries and call-and-recall, and describing the screening tests in more detail, including self-collection of samples, HPV nucleic acid tests and genotyping, cytology and VIA. It advises care in selecting clinically validated HPV tests and ends with footnoted references and WHO contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
